In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
|Articles|August 1, 1997
Oncology NEWS International
- Oncology NEWS International Vol 6 No 8
- Volume 6
- Issue 8
Hopkins' Stem Cell Selection Patents Upheld
WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay Johns Hopkins University, Becton Dickinson & Company, and Baxter Healthcare Corp. $7 million in damages for its willful infringement of patents involving stem cell selection technology.
Advertisement
WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay JohnsHopkins University, Becton Dickinson & Company, and Baxter HealthcareCorp. $7 million in damages for its willful infringement of patents involvingstem cell selection technology.
The judge also ordered an injunction against CellPro's patent-infringingstem cell selection system (Ceprate Stem Cell Concentration System andCeprate LC34 Laboratory Cell Separation System). This injunction will bedelayed in this country until an alternative system, licensed under thepatents, is approved by the FDA.
Johns Hopkins and its licensees requested the delay to ensure that transplantpatients have uninterrupted access to stem cell selection technology. Baxter'sIsolex 300 Magnetic Cell Separator System, already in widespread use inclinical trials, is currently under FDA review.
Articles in this issue
about 29 years ago
Two-Step Approach Urged to Avoid High Tech, Wild Deathabout 29 years ago
Health Insurance Premiums Tax Proposedabout 29 years ago
ODAC Votes Yes on Taxol for Kaposi's Sarcomaabout 29 years ago
Five Principles Help Resolve Ethical Dilemmas in Careabout 29 years ago
Ovarian Cancer Survivors Form National Coalitionabout 29 years ago
Photodynamic Therapy Used in Nonmelanoma Skin Cancerabout 29 years ago
Increased Numbers of Nevi Can Predict Risk of Melanomaabout 29 years ago
With Genetic Tests, Informed Consent Enters Psychosocial Realmabout 29 years ago
Cryoablation May Have Limited Role in Prostate Cancer Treatmentabout 29 years ago
Americans Not Convinced of Value of Watchful WaitingAdvertisement
Related to this article
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in KEYNOTE-365 cohort I.
Posters covered a companion diagnostic for niraparib plus AAP, response biomarkers for radioligand therapy, and genomic profile differences in metastatic CRPC.
Six-year NATALEE data show ribociclib plus an NSAI reduced the risk of death by 19% vs NSAI alone in HR+/HER2- early breast cancer.
Final NSABP B-42 data show 5 additional years of letrozole improved DFS, BCFI, and distant recurrence vs placebo at 15 years, with no OS difference.
Perioperative pembrolizumab plus neoadjuvant cisplatin and gemcitabine did not significantly improve EFS vs placebo in cisplatin-eligible MIBC in KEYNOTE-866.
Hope S. Rugo, MD, FASCO, and Irene M. Kang, MD, discussed ASCENT-03, -04, and TROPION-Breast02 data, sequencing, and toxicity in metastatic TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma
2
What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism
3
Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC
4
Rethinking Patient Selection Strategy for Phase 1 Breast Cancer Trials
5